Paul Hahn, MD, PhD, FASRS

home / authors / paul-hahn-md-phd-fasrs

Articles

Novel Investigational Approaches For the Treatment of Neovascular AMD

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO

December 11th 2023

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

Novel Investigational Approaches for the Treatment of Neovascular AMD

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO

November 30th 2023

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

Faricimab Versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO;Jennifer Lim, MD, FARVO, FASRS

November 27th 2023

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO;Jennifer Lim, MD, FARVO, FASRS

November 15th 2023

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

Achieving Superior Treatment Durability and Outcomes In Neovascular AMD and DME

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO;Aleksandra Rachitskaya, MD, FASRS

November 10th 2023

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

Achieving Superior Treatment Durability and Outcomes in Neovascular AMD and DME

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO;Aleksandra Rachitskaya, MD, FASRS

October 31st 2023

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.